

OSIRIS THERAPEUTICS, INC.
Form 8-K
November 03, 2006

United States
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 2, 2006

OSIRIS THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or other jurisdiction of
incorporation)

001-32966
(Commission File Number)

71-0881115
(IRS Employer
Identification No.)

2001 Aliceanna Street, Baltimore, Maryland
(Address of principal executive offices)

21231
(Zip Code)

Registrant's telephone number, including area code: **(410) 522 - 5005**

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02. Results of Operations and Financial Condition

On November 2, 2006, Osiris Therapeutics, Inc. (Osiris) issued a press release announcing our financial results for the third quarter and nine months ended September 30, 2006, as well as other information. The full text of the Press Release and accompanying Financial Tables issued on November 2, 2006 is set forth in Exhibit 99.1 hereto.

1

The information included herein, including Exhibit 99.1 furnished herewith, shall not be deemed to be filed for purposes of Section 18 of the Securities Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such filing.

ITEM 9.01. Financial Statements and Exhibits

(d) *Exhibits.*

99.1 Press Release dated November 2, 2006 and accompanying Financial Tables of Osiris Therapeutics, Inc.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Osiris has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

OSIRIS THERAPEUTICS, INC.

Dated: November 2, 2006

By:

/s/ CARY J. CLAIBORNE
Cary J. Claiborne
Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release dated November 2, 2006 and accompanying Financial Tables, of Osiris Therapeutics, Inc.
